Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo
E. Helen Kemp, … , Anthony P. Weetman, Philip F. Watson
E. Helen Kemp, … , Anthony P. Weetman, Philip F. Watson
Published April 1, 2002
Citation Information: J Clin Invest. 2002;109(7):923-930. https://doi.org/10.1172/JCI14643.
View: Text | PDF
Article Immunology

The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo

  • Text
  • PDF
Abstract

Vitiligo is a common depigmenting disorder resulting from the loss of melanocytes in the skin. The pathogenesis of the disease remains obscure, although autoimmune mechanisms are thought to be involved. Indeed, autoantibodies and autoreactive T lymphocytes that target melanocytes have been reported in some vitiligo patients. The objective of this study was to identify pigment cell antigens that are recognized by autoantibodies in vitiligo. Using IgG from vitiligo patients to screen a melanocyte cDNA phage-display library, we identified the melanin-concentrating hormone receptor 1 (MCHR1) as a novel autoantigen related to this disorder. Immunoreactivity against the receptor was demonstrated in vitiligo patient sera by using radiobinding assays. Among sera from healthy controls and from patients with autoimmune disease, none exhibited immunoreactivity to MCHR1, indicating a high disease specificity for Ab’s against the receptor. Inhibition of MCH binding to its receptor by IgG from vitiligo patients was also shown.

Authors

E. Helen Kemp, Elizabeth A. Waterman, Brian E. Hawes, Kim O’Neill, Raju V.S.R.K. Gottumukkala, David J. Gawkrodger, Anthony P. Weetman, Philip F. Watson

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
SDS-PAGE and autoradiography of in vitro–translated MCHR1. MCHR1 was pro...
SDS-PAGE and autoradiography of in vitro–translated MCHR1. MCHR1 was produced in vitro in TnT T7 Coupled Reticulocyte Lysate System. To allow glycosylation of MCHR1, canine pancreatic microsomal membranes were added to the transcription-translation reaction. In vitro–translated MCHR1 (lane 1); In vitro–translated and –glycosylated MCHR1 (lane 2).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts